Antag Therapeutics

Investment area

Seed Investments

Region

Europe

Date of investment

april 2017

The team has developed an expertise around the role of GIP (Gastric inhibitory polypeptide) in diabetes and obesity. ANTAG is a spinout of the University of Copenhagen.

Visit site

Contact

Jeroen Bakker

Principal

Department: Seed Investments

Jeroen Bakker joined Seed Investments in 2018.

Jeroen currently holds several board roles and led the investment in Adcendo and Rappta Therapeutics. Prior to joining Novo, Jeroen worked at M Ventures, the corporate venture capital arm of Merck, where he focused on Seed and Series A investments across Europe, United States Israel. He was instrumental in the Artsavit Ltd investment and served on multiple boards. Jeroen held a variety of operational biotech roles in companies like Syntaxin (acquired by Ipsen), Inthera and ISD Immunotech. Prior to joining biotech, he was a Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego.

Jeroen holds a PhD in Immunology from the University of Amsterdam, an MSc in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship and an BSc from the Technical University of Delft. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology and a member of REBBLS, a Danish networking organization focusing on young biotech entrepreneurs.

Related news